Status:
UNKNOWN
A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint
Lead Sponsor:
Agendia
Conditions:
Colon Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to enroll 785 eligible stage II colon cancer patients in order to validate the performance of ColoPrint in estimating 3-year relapse rate. Secondary objectives include compar...
Detailed Description
Primary Objective • To validate the performance of ColoPrint in estimating the 3-year relapse rate in patients with stage II colorectal cancer. Secondary Objectives • To assess the feasibility of us...
Eligibility Criteria
Inclusion
- age ≥ 18 years
- adenocarcinoma of the colon or rectum
- stage II-III, planned to be treated with radical surgery
Exclusion
- prior malignancy with the exception of basal cell carcinoma or cervical dysplasia
- any neo-adjuvant therapy
- synchronous tumors
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT00903565
Start Date
September 1 2008
End Date
December 1 2019
Last Update
January 9 2019
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Glendale Memorial Hospital
Glendale, California, United States, 91204
2
South Orange County Surgical Medical Group
Laguna Hills, California, United States, 92653
3
Long Beach Memorial Medical Center
Long Beach, California, United States, 90806
4
Sutter Roseville Medical Center /Research
Roseville, California, United States, 95661